February 12, 2026 01:53 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bangladesh poll manifestos mirror India’s welfare schemes as BNP, Jamaat bet big on women, freebies | Drama ends: Pakistan makes U-turn on India boycott, to play T20 World Cup clash as per schedule | ‘Won’t allow any impediment in SIR’: Supreme Court pulls up Mamata govt over delay in sharing officers’ details | India-US trade deal: ‘Negotiations always two-way’, says Amul MD amid farmers’ concerns | Khamenei breaks 37-year-old ritual for first time amid escalating Iran-US tensions | India must push for energy independence amid global uncertainty: Vedanta chairman Anil Agarwal | Kanpur horror: Lamborghini driven by businessman’s son rams vehicles, injures six | ‘Namaste Trump beat Howdy Modi’: Congress slams PM Over India-US trade deal | Historic India-US trade pact: Tariffs cut, $500B market opportunity unlocked! | Big call from RBI: Repo rate stays at 5.25%, neutral stance continues
COVID-19 Vaccine
AdarPoonawala Twitter page

COVID-19 vaccine is safe, says Serum Institute of India on side effect claims  

| @indiablooms | Dec 01, 2020, at 10:13 pm

Pune-based  Serum Institute of India's (SII) said its 'COVISHIELD' vaccine is safe and immunogenic after a volunteer claimed that he suffered neurological and psychological side effects after taking a shot of the vaccine.

Rejecting all allegations, the institute said: "The incident with the Chennai volunteer though highly unfortunate was in no way induced by the vaccine and Serum Institute of India is sympathetic with the volunteer's medical condition. "

"However, we would like to clarify that all the requisite regulatory and ethical processes and guidelines were followed diligently and strictly," the institute said.

"The concerned authorities were informed and the Principal Investigator, DSMB and the Ethics Committee independently cleared and reckoned it as a non-related issue to the vaccine trial. Post which we submitted all the reports and data related to the incident to the DCGI. It is only after we cleared all the required processes that we continued with the trials," read the statement.

The Pune based institute said the vaccine will not be released for mass use unless it is proven immunogenic, and safe.  

"Taking into consideration the complexities and existing misnomers about vaccination and immunisation; the legal notice was sent therefore to safeguard the reputation of the company which is being unfairly maligned," it said.

The institute is conducting clinical trials of the  AstraZeneca-Oxford's Covid-19 vaccine in India.

The phase-3 clinical trial of the vaccine is currently being made across India.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.